Passage Bio Inc (NAS:PASG)
$ 0.7925 -0.0075 (-0.94%) Market Cap: 49.41 Mil Enterprise Value: -11.14 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 37/100

Passage Bio Inc to Review Interim FTD Data Transcript

Dec 20, 2023 / 01:30PM GMT
Release Date Price: $0.8148 (+7.35%)
Operator

Thank you for holding. Good morning and welcome to the Passage Bio Conference Call. At this time, all participants are in a listen only mode. Following the formal remarks, we will open up the call for your questions. Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn it over to Stuart Henderson, Vice President of Corporate Development and Investor Relations. Stuart, please proceed.

Stuart Henderson Passage Bio
Inc. - VP of Corporate Development & IR

Thank you, operator. Today, we will review interim results from the global uplifted Phase one two clinical trial of PBFTO 2in frontotemporal dementia. Please refer to the press release issued recently and the slides that we will be using on today's call on the Investors & News section of the Passage Bio website.

Before we begin, I'd like to remind you that our presentation will contain forward-looking statements based on our current expectations and beliefs of future events. As of today, these statements are subject to a number of risks and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot